FDA OKs Daraxonrasib Pancreatic Cancer Preapproval Access

by | May 1, 2026 | Health

Spread the love
FDA authorizes an expanded access treatment protocol after the oral RAS(ON) inhibitor doubled survival for metastatic patients in a phase 3 trial.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments